{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T23:24:26Z","timestamp":1782861866307,"version":"3.54.5"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T00:00:00Z","timestamp":1756857600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T00:00:00Z","timestamp":1756857600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s12325-025-03335-z","type":"journal-article","created":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T07:38:04Z","timestamp":1756885084000},"page":"5529-5546","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pharmacokinetic Bridging Between an Autoinjector and a Prefilled Syringe Following Subcutaneous Administration of Mirikizumab in Healthy Participants"],"prefix":"10.1007","volume":"42","clinical-trial-number":[{"clinical-trial-number":"nct04607733","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05069896","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4064-6805","authenticated-orcid":false,"given":"Xin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7184-8776","authenticated-orcid":false,"given":"Yuki","family":"Otani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0549-5455","authenticated-orcid":false,"given":"Christopher D.","family":"Payne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7989-5764","authenticated-orcid":false,"given":"Nathan J.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5417-3062","authenticated-orcid":false,"given":"Laiyi","family":"Chua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Escobar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sihe","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galen","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,3]]},"reference":[{"key":"3335_CR1","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/nrd.2018.183","volume":"18","author":"AC Anselmo","year":"2019","unstructured":"Anselmo AC, Gokarn Y, Mitragotri S. Non-invasive delivery strategies for biologics. Nat Rev Drug Discov. 2019;18:19\u201340. https:\/\/doi.org\/10.1038\/nrd.2018.183.","journal-title":"Nat Rev Drug Discov"},{"key":"3335_CR2","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1002\/jcph.2322","volume":"63","author":"YF Wen","year":"2023","unstructured":"Wen YF, Ji P, Schrieber SJ, et al. Evaluation of truncated AUC as an alternative measure to assess pharmacokinetic comparability in bridging biologic-device using prefilled syringes and autoinjectors. J Clin Pharmacol. 2023;63:1417\u201329. https:\/\/doi.org\/10.1002\/jcph.2322.","journal-title":"J Clin Pharmacol"},{"key":"3335_CR3","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1080\/19420862.2017.1392424","volume":"10","author":"Z Li","year":"2018","unstructured":"Li Z, Easton R. Practical considerations in clinical strategy to support the development of injectable drug-device combination products for biologics. MAbs. 2018;10:18\u201333. https:\/\/doi.org\/10.1080\/19420862.2017.1392424.","journal-title":"MAbs"},{"key":"3335_CR4","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1208\/s12248-020-0433-8","volume":"22","author":"P Hu","year":"2020","unstructured":"Hu P, Wang J, Florian J, et al. Systematic review of device parameters and design of studies bridging biologic-device combination products using prefilled syringes and autoinjectors. AAPS J. 2020;22:52. https:\/\/doi.org\/10.1208\/s12248-020-0433-8.","journal-title":"AAPS J"},{"key":"3335_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/pharmacy10040087","volume":"10","author":"Y Liu","year":"2022","unstructured":"Liu Y, S\u00f6derberg J, Chao J. Adherence to and persistence with adalimumab therapy among Swedish patients with Crohn\u2019s disease. Pharmacy (Basel). 2022;10:87. https:\/\/doi.org\/10.3390\/pharmacy10040087.","journal-title":"Pharmacy (Basel)"},{"key":"3335_CR6","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1007\/s12325-018-0759-0","volume":"35","author":"N Maniadakis","year":"2018","unstructured":"Maniadakis N, Toth E, Schiff M, et al. A targeted literature review examining biologic therapy compliance and persistence in chronic inflammatory diseases to identify the associated unmet needs, driving factors, and consequences. Adv Ther. 2018;35:1333\u201355. https:\/\/doi.org\/10.1007\/s12325-018-0759-0.","journal-title":"Adv Ther"},{"key":"3335_CR7","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1016\/j.jsps.2021.09.004","volume":"29","author":"A Roy","year":"2021","unstructured":"Roy A, Geetha RV, Magesh A, Vijayaraghavan R, Ravichandran V. Autoinjector \u2013 a smart device for emergency cum personal therapy. Saudi Pharm J. 2021;29:1205\u201315. https:\/\/doi.org\/10.1016\/j.jsps.2021.09.004.","journal-title":"Saudi Pharm J"},{"key":"3335_CR8","unstructured":"OMVOH [US Highlights of Prescribing Information]. Indianapolis: Eli Lilly and Company; 2025. https:\/\/pi.lilly.com\/us\/omvoh-uspi.pdf. Accessed 28 Feb 2025."},{"key":"3335_CR9","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1056\/NEJMoa2207940","volume":"388","author":"G D'Haens","year":"2023","unstructured":"D\u2019Haens G, Dubinsky M, Kobayashi T, et al. Mirikizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2023;388:2444\u201355. https:\/\/doi.org\/10.1056\/NEJMoa2207940.","journal-title":"N Engl J Med"},{"key":"3335_CR10","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1016\/S0140-6736(24)01762-8","volume":"404","author":"M Ferrante","year":"2024","unstructured":"Ferrante M, D\u2019Haens G, Jairath V, et al. Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn\u2019s disease: a phase\u00a03, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study. Lancet. 2024;404:2423\u201336. https:\/\/doi.org\/10.1016\/S0140-6736(24)01762-8.","journal-title":"Lancet"},{"key":"3335_CR11","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/jdv.13768","volume":"31","author":"K Callis Duffin","year":"2017","unstructured":"Callis Duffin K, Bagel J, Bukhalo M, et al. Phase\u00a03, open-label, randomized study of the pharmacokinetics, efficacy and safety of ixekizumab following subcutaneous administration using a prefilled syringe or an autoinjector in patients with moderate-to-severe plaque psoriasis (UNCOVER-A). J Eur Acad Dermatol Venereol. 2017;31:107\u201313. https:\/\/doi.org\/10.1111\/jdv.13768.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"3335_CR12","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.2147\/ppa.S170636","volume":"12","author":"VL Stauffer","year":"2018","unstructured":"Stauffer VL, Sides R, Lanteri-Minet M, et al. Comparison between prefilled syringe and autoinjector devices on patient-reported experiences and pharmacokinetics in galcanezumab studies. Patient Prefer Adher. 2018;12:1785\u201395. https:\/\/doi.org\/10.2147\/ppa.S170636.","journal-title":"Patient Prefer Adher"},{"key":"3335_CR13","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1007\/s40262-023-01281-z","volume":"62","author":"L Chua","year":"2023","unstructured":"Chua L, Friedrich S, Zhang XC. Mirikizumab pharmacokinetics in patients with moderately to severely active ulcerative colitis: results from phase\u00a0III LUCENT studies. Clin Pharmacokinet. 2023;62:1479\u201391. https:\/\/doi.org\/10.1007\/s40262-023-01281-z.","journal-title":"Clin Pharmacokinet"},{"key":"3335_CR14","doi-asserted-by":"publisher","unstructured":"Chua L, Otani Y, Lin Z, Friedrich S, Durand F, Zhang XC. Mirikizumab pharmacokinetics and exposure-response in patients with moderately-to-severely active Crohn\u2019s disease: results from two randomized studies. Clin Transl Sci. (In press). https:\/\/doi.org\/10.1111\/cts.70320","DOI":"10.1111\/cts.70320"},{"key":"3335_CR15","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1007\/s12325-025-03158-y","volume":"42","author":"Y Otani","year":"2025","unstructured":"Otani Y, Feagan BG, D\u2019Haens GR, et al. Pharmacokinetic comparability and safety between original and citrate-free mirikizumab formulations for subcutaneous injections: results from three clinical trials. Adv Ther. 2025;42:2369\u201384. https:\/\/doi.org\/10.1007\/s12325-025-03158-y.","journal-title":"Adv Ther"},{"key":"3335_CR16","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1111\/j.1365-2702.2005.01121.x","volume":"14","author":"A Williamson","year":"2005","unstructured":"Williamson A, Hoggart B. Pain: a review of three commonly used pain rating scales. J Clin Nurs. 2005;14:798\u2013804. https:\/\/doi.org\/10.1111\/j.1365-2702.2005.01121.x.","journal-title":"J Clin Nurs"},{"key":"3335_CR17","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/s0304-3959(97)00005-5","volume":"72","author":"SL Collins","year":"1997","unstructured":"Collins SL, Moore RA, McQuay HJ. The visual analogue pain intensity scale: what is moderate pain in millimetres? Pain. 1997;72:95\u20137. https:\/\/doi.org\/10.1016\/s0304-3959(97)00005-5.","journal-title":"Pain"},{"key":"3335_CR18","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1002\/wics.1310","volume":"6","author":"SC Chow","year":"2014","unstructured":"Chow SC. Bioavailability and bioequivalence in drug development. Wiley Interdiscipl Rev Comput Stat. 2014;6:304\u201312. https:\/\/doi.org\/10.1002\/wics.1310.","journal-title":"Wiley Interdiscipl Rev Comput Stat"},{"key":"3335_CR19","unstructured":"US Department of Health and Human Services. Bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an ANDA guidance for industry. 2021. https:\/\/www.fda.gov\/media\/87219\/download. Accessed 19 Sept 2024."},{"key":"3335_CR20","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1208\/s12248-012-9367-0","volume":"14","author":"WF Richter","year":"2012","unstructured":"Richter WF, Bhansali SG, Morris ME. Mechanistic determinants of biotherapeutics absorption following SC administration. AAPS J. 2012;14:559\u201370. https:\/\/doi.org\/10.1208\/s12248-012-9367-0.","journal-title":"AAPS J"},{"key":"3335_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2024.124446","volume":"661","author":"M de Lucio","year":"2024","unstructured":"de Lucio M, Leng Y, Wang H, Vlachos PP, Gomez H. Modeling drug transport and absorption in subcutaneous injection of monoclonal antibodies: impact of tissue deformation, devices, and physiology. Int J Pharm. 2024;661:124446. https:\/\/doi.org\/10.1016\/j.ijpharm.2024.124446.","journal-title":"Int J Pharm"},{"key":"3335_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/antib8040056","volume":"8","author":"VA Thomas","year":"2019","unstructured":"Thomas VA, Balthasar JP. Understanding inter-individual variability in monoclonal antibody disposition. Antibodies (Basel). 2019;8:56. https:\/\/doi.org\/10.3390\/antib8040056.","journal-title":"Antibodies (Basel)"},{"key":"3335_CR23","doi-asserted-by":"publisher","first-page":"1000216","DOI":"10.4172\/2155-6156.1000216","volume":"3","author":"O Akkus","year":"2012","unstructured":"Akkus O, Oguz A, Uzunlulu M, Kizilgul M. Evaluation of skin and subcutaneous adipose tissue thickness for optimal insulin injection. J Diabetes Metab. 2012;3:1000216. https:\/\/doi.org\/10.4172\/2155-6156.1000216.","journal-title":"J Diabetes Metab"},{"key":"3335_CR24","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1002\/cpt.3305","volume":"116","author":"S Friedrich","year":"2024","unstructured":"Friedrich S, Chua L, Adams DH, Crandall W, Zhang XC. Mirikizumab exposure-response relationships in patients with moderately-to-severely active ulcerative colitis in randomized phase\u00a0II and III studies. Clin Pharmacol Ther. 2024;116:435\u201347. https:\/\/doi.org\/10.1002\/cpt.3305.","journal-title":"Clin Pharmacol Ther"},{"key":"3335_CR25","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/(SICI)1520-6017(200003)89:3<297::AID-JPS2>3.0.CO;2-P","volume":"89","author":"CJ Porter","year":"2000","unstructured":"Porter CJ, Charman SA. Lymphatic transport of proteins after subcutaneous administration. J Pharm Sci. 2000;89:297\u2013310. https:\/\/doi.org\/10.1002\/(SICI)1520-6017(200003)89:3<297::AID-JPS2>3.0.CO;2-P.","journal-title":"J Pharm Sci"},{"key":"3335_CR26","first-page":"570","volume":"44","author":"RF Uren","year":"2003","unstructured":"Uren RF, Howman-Giles R, Thompson JF. Patterns of lymphatic drainage from the skin in patients with melanoma. J Nucl Med. 2003;44:570\u201382.","journal-title":"J Nucl Med"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03335-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03335-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03335-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T21:02:32Z","timestamp":1762030952000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03335-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,3]]},"references-count":26,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["3335"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03335-z","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,3]]},"assertion":[{"value":"13 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Xin Zhang, Yuki Otani, Christopher D. Payne, Nathan J. Morris, Laiyi Chua, Rodrigo Escobar, Sihe Wang, and Galen Shi are employees and shareholders of Eli Lilly and Company.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Both studies were conducted in accordance with the study protocols and with consensus ethics principles derived from international ethics guidelines, including the Declaration of Helsinki and Council for International Organizations of Medical Sciences International Ethical Guidelines, International Council for Harmonisation Good Clinical Practice Guidelines, and applicable laws and regulations. The study protocols were approved by the institutional review boards at each study site. All participants entered into the study provided written informed consent. Ethical review boards were in place for both studies: the WCG Independent Review Board was the overall (\u201cmaster\u201d) ethics committee for Study AMBW, and the Salus Institutional Review Board was the overall (\u201cmaster\u201d) ethics committee for Study AMBX. Informed consent forms, required to provide details about why the research was being done and what it would involve, were approved by the respective review boards and provided to participants. Subsequent dated written informed consent was required by each participant before the participant could participate in the study. The informed consent forms also noted that study data which did not directly identify participants could be published.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}